Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

News

April 16, 2024
PRESS RELEASE: On April 12, 2024, a new research paper was published in Oncotarget, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.” continue reading »

Synergistic Effects of Drug Combinations Targeting AML Cells

Oncotarget

April 11, 2024
In this new study, researchers investigated a promising new approach to acute myeloid leukemia (AML) therapy by combining multiple drugs to enhance cytotoxic effects on AML cells. continue reading »

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

News

April 11, 2024
PRESS RELEASE: On April 8, 2024, a new research paper was published in Oncotarget, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.” continue reading »

Identifying Biomarkers for Predicting Paclitaxel Response

Oncotarget

March 28, 2024
In this research perspective, researchers discuss causal and correlative approaches to identify potential biomarkers for predicting paclitaxel response. continue reading »

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

Oncotarget

March 27, 2024
PRESS RELEASE: On March 19, 2024, a new research paper was published in Oncotarget, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” continue reading »